Gaetano Lardieri has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness of medically monitored ibogaine with protocolized MOUD rescue versus buprenorphine or methadone initiation for opioid use disorder: a decision-analytic model

    by T Wagner, Gaetano Lardieri

    Introduction: Ibogaine is being studied for opioid use disorder (OUD), but a single episode adds long-term value only if early responses last. We compared a medically monitored ibogaine episode with protocolized medication for OUD (MOUD) rescue against starting buprenorphine or methadone.,Methods: We built a weekly cohort state-transition model of treatment-presenting, eligible U.S. adults over 10 years (health care sector perspective, 2024 US$, 3% discounting). The model tracks response, first return to use, MOUD status, opioid use and mortality. Without participant-level relapse data, durability was partially identified from one cohort's grouped follow-up under three curves, none a base case. Acquisition price was excluded; threshold prices are reported. One-way, structural and probabilistic sensitivity analyses were run, the latter sampling source uncertainty only, conditional on each curve and retention schedule.,Results: Versus buprenorphine, incremental QALYs per person were 0.0024, 0.0152 and 0.0125 under the fast-bound, Tier-1 upper-edge and proportional-transport curves, at $3,937 to $6,290 more before acquisition. ICERs were $2,673,000, $259,562 and $353,661 per QALY ($2,528,000, $217,217 and $307,945 versus methadone). Under a conservative mortality mapping the strategy caused 0.28 to 0.39 more deaths per 1,000; with background mortality after response it caused fewer, and Tier-1 ICERs were $86,535 and $75,705 per QALY. No non-negative acquisition price met $150,000 per QALY. Cost-effectiveness at $100,000 per QALY required a post-month-12 return half-life of at least 89 to 195 weeks (reference 44.4). Crediting one participant with unresolved treatment-course history gave $22,684 per QALY versus buprenorphine. In conditional probabilistic analyses, none of the 1,000 parameter-uncertainty draws was cost-effective at $100,000 per QALY in any principal or retention-conditioned analysis.,Conclusions: Under the principal evidence and a conservative mortality mapping, medically monitored ibogaine with protocolized MOUD rescue was not cost-effective at willingness-to-pay thresholds up to $150,000 per QALY versus starting buprenorphine or methadone, even before including an ibogaine acquisition price. The decision could change with durability beyond one year, the classification of one participant with unresolved treatment-course history, the day-28 response definition (the available-case reading), mortality after response, and the monitoring setting and state acute-care cost gradients. Linked participant-level data are the priority.

  • Open Access

    Antioxidants Derived from Natural Products Reduce Radiative Damage in Cultured Retinal Glia to Prevent Oxidative Stress

    by Richard N. Cliver, Natalia Castro, Thais Russomano, Gaetano Lardieri, Lindsay Quarrie, Helena van der Merwe, Maribel Vazquez

    Retinal pathologies have been heavily studied in response to radiation and microgravity, including spaceflight-associated neuro-ocular syndrome (SANS), which is commonly developed in space flight. SANS has been characterized in clinical studies of astronauts returning to Earth and includes a range of symptoms, such as globe flattening, optic-disc edema, retinal folds, and retinal ischemia. In cases of retinal insult, Müller glia (MG) cells respond via neuroprotective gliotic responses that may become destructive to produce glial scarring and vison loss over time. Retinal pathology is further impacted by the production of excessive reactive oxygen species (ROS) that stimulate retinal inflammation and furthers the gliosis of MG. Neuroprotectants derived from natural products (NPs) able to scavenge excess ROS and mitigate long-term, gliotic responses have garnered recent interest, especially among mature and aging adults. The natural antioxidants aloin and ginkgolide A flavonoids, derived from Aloe vera and Ginkgo biloba species, respectively, have been of particular interest due to their recent use in other nervous-system studies. The current study examined MG behaviors in response to different doses of aloin and ginkgolide A over time by measuring changes in morphology, survival, and ROS production within microscale assays. The study was further enhanced by using galactic cosmic rays (GCR) at the Brookhaven NASA Space Radiation Laboratory to simulate ionizing radiation in low- and high-radiation parameters. Changes in the survival and ROS production of radiation-treated MG were then measured in response to varying dosage of NPs. Our study used in vitro systems to evaluate the potential of NPs to reduce oxidative stress in the retina, highlighting the underexplored interplay between NP antioxidants and MG endogenous responses both in space and terrestrially.